"I was amazed that we could eliminate effective insulin in 90 days, then basal insulin at that point in 7 out of 10 patients," says the creator.
Specialists in their new review found that a drug used for weight reduction - semaglutide - could help reduce or completely reduce insulin injections in those individuals diagnosed with type 1 diabetes, leaving the creators paralyzed about the wonders of this drug .
The drug known as Ozempic or Wegovy became famous last year for its weight reduction effects. As reports suggest, the former is used to treat type 2 diabetes, while Wego's is for weight reduction.
In a review distributed in the New Britain Diary of Medication, experts examined data from 10 individuals with type 1 diabetes who were taking the medication. All of them did not inject insulin with dinner, and in half a year 7 out of 10 stopped using insulin completely.
As lead author Dr Paresh Dandona alluded to the two types of insulin – one active and one longer-acting – he said: “I was absolutely amazed that we could knock out the active insulin in 90 days and then the basal insulin in seven of them. 10 patients."
"It was practically like science fiction," Dandona said.
Individuals struggle with sugar control problems, but the treatment and reasons for the diseases are not very similar.
In type 1 diabetes, the body begins to kill the beta cells that produce insulin – used to take sugar from the blood into the cells for energy. Insulin is thus necessary in light of the fact that the framework ceases to make it.
Although in type 2 diabetes, the beta cells in the pancreas do not supply enough insulin and the body also does not respond to insulin, causing a condition called insulin obstruction. In this regard, drugs are used in a similar way.
Semaglutide breakpoints
Dr. Dandona showed his commitment to changing the treatment of type 1 diabetes by saying, "I am extremely excited about this. I believe that changing the state of the treatment of type 1 diabetes is possible."
Similarly, he expressed that there should be a bigger message, adding that he has now gathered in a gathering of diabetologists from different areas across the country. Whenever grants have been obtained, a review can begin.
Specialists praised the new results and called for more testing before recommending to individuals.
Dr. Michael Natter, an endocrinologist at NYU Langone Wellbeing, said, "You can't make a big deal about the case in light of a small, uncontrolled study. We really want to see more and bigger investigations."
He added that he is "very energetic and hopeful, but still guarded and that as an individual with type 1 diabetes, he has a dog in the fight."
"The decision to zero out the recently analyzed patients was great," said Dr. Vanita Aroda, chief of diabetes clinical trials at Brigham and Ladies' Emergency Clinic in Boston.
She said the discoveries are extremely remarkable. Huge examinations should be completed and this is the source of inspiration. We should study the population of patients with type 1 diabetes to see if they can benefit from such treatment."
0 Comments